|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.70 USD | +3.63% |
|
+8.54% | +17.40% |
| 06-30 | Zai Lab Insider Sold Shares Worth $428,545, According to a Recent SEC Filing | MT |
| 06-16 | Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 33.3 | +66.68% | 12 | ||||||
| 822.48 | +23.14% | 28 | ||||||
| 287.95 | +15.18% | 19 | ||||||
| 96.64 | +10.89% | 16 | ||||||
| 2,052,158.8 | +54.88% | 24 | ||||||
| 47.89 | -37.44% | 19 | ||||||
| 222.83 | +12.03% | 31 | ||||||
| 111.45 | -5.96% | 22 | ||||||
| 101.25 | +35.21% | 25 | ||||||
| 102.47 | +13.64% | 22 | ||||||
| 485.42 | +1.38% | 12 | ||||||
| 276.56 | +11.09% | 21 | ||||||
| 87.69 | +46.23% | 26 | ||||||
| 349.78 | -5.78% | 9 | ||||||
| 458,000 | +52.67% | 5 | ||||||
| - | - | 61.5 | +20.39% | 1 | ||||
| 14.4 | +60.1% | 12 | ||||||
| 77.7 | -17.05% | 10 | ||||||
| 72.5 | +15.56% | 2 | ||||||
| 30.05 | +103.87% | 9 | ||||||
| Average | 125,672.03 | +23.84% | 16 | ||||||
| Weighted average by Cap. | 210,338.99 | +17.81% | 20 |
- Stock Market
- Stocks
- ZLAB Stock
- Sector Zai Lab Limited
- Sector consensus
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
